| Literature DB >> 36199818 |
Syeda Samar Mustafa1, Rida Batool1, Muhammad Kamran2, Hasnain Javed3, Nazia Jamil1.
Abstract
Introduction: Wastewaters carrying thousands of human specimens from the community and representing the diversity of antibiotic-resistant bacteria (ARB) and antibiotic-resistance genes (ARGs) directly from the community mirror the extent of AR spread in the community and environment. This study aimed to investigate the occurrence and distribution of antibiotic-resistant ESKAPEE bacteria in the community versus clinical settings through monitoring nonclinical and clinical wastewaters. Methodology: Seven wastewater samples were collected from different environmental sources. Isolates were obtained on general and selective media, biochemically characterized and antimicrobial-susceptibility tests performed by disk diffusion against 13 antibiotics according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines using MastDisc disk cartridges, and 16S rRNA metagenomic analysis was performed for two water samples.Entities:
Keywords: ESKAPEE; IntI1; metagenome; resistance profiling; wastewater
Year: 2022 PMID: 36199818 PMCID: PMC9527703 DOI: 10.2147/IDR.S368886
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.177
Figure 1Distribution of ESKAPEE bacteria among wastewater samples according to the present study. The number of each prominent ESKAPEE isolate in a given sample is shown in percentage. For hospital wastewater that contained all ESKAPEE pathogens, the percentages shown are in the same order as that of the acronym.
Figure 2Percentage of ESKAPEE bacteria in wastewater sources. Gram-negative bacteria were predominant in both clinical and nonclinical wastewater, while Gram positive species were recovered exclusively from clinical wastewater.
Figure 3Percentage of drug-resistant isolates from clinical and nonclinical wastewater. Extensive resistance to the 13 drugs used in this study was observed, irrespective of wastewater source, indicating the selection of XDRs in the natural environment.
Antibiotic-resistance profiles of ESKAPEE bacterial isolates. Resistance was found to be 100% in most of the ESKAPEE bacteria. MAR index of 1 for most of the isolates validated the results by indicating that most were resistant to all the antibiotics included in AST
| Isolates | Resistance pattern | Resistance; n (%) | MARI |
|---|---|---|---|
| H1A | PRL-PTZ-CXM-MEM-C-LEV-AMK-GM-VA-CLA-ATH-CD-LZD | 13 (100) | 1 |
| H1B | PRL-PTZ-CXM-MEM-C-LEV-AMK-GM-VA-CLA-ATH-CD-LZD | 13 (100) | 1 |
| H1C | PRL-PTZ-CXM-MEM-C-LEV-AMK-GM-VA-CLA-ATH-CD-LZD | 13 (100) | 1 |
| H1D | PRL-PTZ-CXM-MEM-C-LEV-AMK-GM-VA-CLA-ATH-CD-LZD | 13 (100) | 1 |
| H1E | PRL-PTZ-CXM-MEM-C-LEV-AMK-GM-VA-CLA-ATH-CD-LZD | 13 (100) | 1 |
| H2A | PRL-PTZ-CXM-MEM-C-LEV-AMK-GM-VA-CLA-ATH-CD-LZD-NOR | *14 (100) | 1 |
| H2B | PRL-PTZ-CXM-MEM-C-LEV-AMK-GM-VA-CLA-ATH-CD-LZD-NOR | 14 (100) | 1 |
| H2C | PRL-PTZ-CXM-MEM-C-LEV-AMK-GM-VA-CLA-ATH-CD-LZD-NOR | 14 (100) | 1 |
| H2D | PRL-PTZ-CXM-MEM-C-LEV-AMK-GM-VA-CLA-ATH-CD-LZD-NOR | 14 (100) | 1 |
| H2E | PRL-PTZ-CXM-MEM-C-LEV-AMK-GM-VA-CLA-ATH-CD-LZD-NOR | 14 (100) | 1 |
| H2F | PRL-PTZ-CXM-MEM-C-LEV-AMK-GM-VA-CLA-ATH-CD-LZD-NOR | 14 (100) | 1 |
| H2G | PRL-PTZ-CXM-MEM-C-LEV-AMK-GM-VA-CLA-ATH-CD-LZD-NOR | 14 (100) | 1 |
| H2H | PRL-PTZ-CXM-MEM-C-LEV-VA-ATH-CD-LZD | 10 (71.4%) | 0.71 |
| H2I | PRL-PTZ-CXM-MEM-C-LEV-AMK-GM-VA-CLA-ATH-CD-LZD-NOR | 13 (92.8) | 0.9 |
| H2J | PRL-PTZ-CXM-MEM-C-LEV-AMK-GM-VA-CLA-ATH-CD-LZD-NOR | 13 (92.8) | 0.9 |
| H2K | PRL-PTZ-CXM-MEM-C-LEV-VA-ATH-CD-LZD | 10 (71.4) | 0.71 |
| H3A | PRL-PTZ-CXM-MEM-C-LEV-CLA-ATH-AMK-GM-VA-CD | 12 (92.3) | 0.9 |
| H3B | PRL-PTZ-CXM-MEM-C-LEV-AMK-GM-VA-CLA-ATH-CD-LZD | 13 (100) | 1 |
| H3C | PRL-PTZ-CXM-MEM-C-LEV-VA-CLA-CD-LZD | 11 (84.6) | 0.8 |
| H3D | PRL-PTZ-CXM-MEM-C-LEV-AMK-GM-VA-CLA-ATH-CD | 12 (92.3) | 0.9 |
| H3E | PRL-PTZ-CXM-MEM-C-LEV-AMK-GM-VA-CLA-ATH-CD | 12 (92.3) | 0.9 |
| H3F | PRL-PTZ-CXM-MEM-C-LEV-VA-CLA-CD-LZD | 13 (100) | 1 |
| H3G | PRL-PTZ-CXM-MEM-C-LEV-AMK-GM-VA-CLA-ATH-CD-LZD | 13 (100) | 1 |
| H3H | PRL-PTZ-CXM-MEM-C-LEV-AMK-GM-VA-CLA-ATH-CD-LZD | 13 (100) | 1 |
| H3I | PRL-PTZ-CXM-MEM-C-LEV-AMK-GM-VA-CLA-ATH-CD-LZD | 13 (100) | 1 |
| M1A | PRL-PTZ-CXM-MEM-C-LEV-AMK-GM-VA-CLA-ATH-CD-LZD | 13 (100) | 1 |
| M1B | PRL-PTZ-CXM-MEM-C-LEV-AMK-GM-VA-CLA-ATH-CD-LZD | 13 (100) | 1 |
| M1C | PRL-PTZ-CXM-MEM-C-LEV-AMK-GM-VA-CLA-ATH-CD-LZD | 13 (100) | 1 |
| M2A | PRL-PTZ-CXM-MEM-C-LEV-AMK-GM-VA-CLA-ATH-CD-LZD | 13 (100) | 1 |
| M2B | PRL-PTZ-CXM-MEM-C-LEV-AMK-GM-VA-CLA-ATH-CD | 12 (92.3) | 0.9 |
| M2C | PRL-PTZ-CXM-MEM-C-LEV-GM-VA-CLA-ATH-CD | 12 (92.3) | 0.9 |
| M2D | PRL-PTZ-CXM-MEM-C-LEV-AMK-GM-VA-CLA-ATH-CD-LZD | 13 (100) | 1 |
| M2E | PRL-PTZ-CXM-MEM-C-LEV-AMK-GM-VA-CLA-ATH-CD-LZD | 13 (100) | 1 |
| M2F | PRL-PTZ-CXM-MEM-C-LEV-AMK-GM-VA-CLA-ATH-CD-LZD | 13 (100) | 1 |
| P1A | PRL-PTZ-CXM-MEM-C-LEV-AMK-GM-VA-CLA-ATH-CD-LZD | 13 (100) | 1 |
| P1B | PRL-PTZ-CXM-MEM-C-LEV-AMK-GM-VA-CLA-ATH-CD-LZD | 13 (100) | 1 |
| P1C | PRL-PTZ-CXM-MEM-C-LEV-AMK-GM-VA-CLA-ATH-CD-LZD | 13 (100) | 1 |
| P1D | PRL-PTZ-CXM-MEM-C-LEV-AMK-GM-VA-CLA-ATH-CD-LZD | 13 (100) | 1 |
| R1A | PRL-PTZ-CXM-MEM-C-LEV-VA-CLA-ATH-CD | 10 (76.9) | 0.76 |
| R1B | PRL-PTZ-CXM-MEM-C-LEV-AMK-GM-VA-CLA-ATH-CD-LZD | 12 (92.3) | 0.9 |
| R1C | PRL-PTZ-CXM-MEM-C-LEV-AMK-GM-VA-CLA-ATH-CD-LZD | 13 (100) | 1 |
| R1D | PRL-PTZ-CXM-MEM-C-LEV-VA-CLA-ATH-CD | 10 (76.9) | 0.76 |
| R1E | PRL-PTZ-CXM-MEM-C-LEV-AMK-GM-VA-CLA-ATH-CD-LZD | 13 (100) | 1 |
Abbreviations: *PRL, piperacillin; PTZ, piperacillin–tazobactam; CXM, cefuroxime; MEM, meropenem; C, ciprofloxacin; LEV, levofloxacin; AMK, amikacin; GM, gentamicin; VA, vancomycin; CLA, clarithromycin; ATH, azithromycin; CD, clindamycin.
Antibiogram of the isolated bacterial species from wastewater sources. Species-wise resistance rate against 13 antibiotics showed only a few isolates
| Antibiotic Resistance No. (%) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Piperacillin (PRL) | Piperacillin–tazobactam (PTZ) | Cefuroxime (CXM) | Meropenem (MEM) | Clarithromycin (CLA) | Azithromycin (ATH) | Clindamycin (CD) | Ciprofloxacin (C) | Levofloxacin (LEV) | Amikacin (AK) | Gentamicin (GM) | Vancomycin (VA) | Linezolid (LZD) | |
| 9 (100) | 9 (100) | 9 (100) | 9 (100) | 9 (100) | 9 (100) | 9 (100) | 9 (100) | 9 (100) | 9 (100) | 9 (100) | 9 (100) | 7 (77.7) | |
| 4 (100) | 4 (100) | 4 (100) | 4 (100) | 4 (100) | 4 (100) | 4 (100) | 4 (100) | 4 (100) | 4 (100) | 4 (100) | 4 (100) | 2 (50) | |
| 4 (100) | 4 (100) | 4 (100) | 4 (100) | 4 (100) | 4 (100) | 4 (100) | 4 (100) | 4 (100) | 3 (75) | 3 (75) | 4 (100) | 4 (100) | |
| 4 (100) | 4 (100) | 4 (100) | 4 (100) | 3 (75) | 4 (100) | 4 (100) | 4 (100) | 4 (100) | 3 (75) | 3 (75) | 4 (100) | 3 (75) | |
| 15 (100) | 15 (100) | 15 (100) | 15 (100) | 14 (93.3) | 15 (100) | 15 (100) | 15 (100) | 15 (100) | 13 (86.6) | 12 (80) | 15 (100) | 13 (86.6) | |
| 5 (100) | 5 (100) | 5 (100) | 5 (100) | 5 (100) | 5 (100) | 5 (100) | 5 (100) | 5 (100) | 4 (80) | 4 (80) | 5 (100) | 4 (80) | |
| 2 (100) | 2 (100) | 2 (100) | 2 (100) | 2 (100) | 2 (100) | 2 (100) | 2 (100) | 2 (100) | 2 (100) | 2 (100) | 2 (100) | 1 (50) | |
Notes: ESKAPEE bacteria were susceptible to just clarithromycin, amikacin and gentamicin. The highest susceptibility observed was to linezolid.
Figure 4Resistance phenotypes of resistant bacteria from clinical and nonclinical wastewaters. Four of seven bacterial species showed multiple drug resistance in addition to extensive drug resistance (red and purple areas), while strains of Gram positive cocci and Enterobacter spp. were found to be extensively drug-resistant (blue and green areas).
Figure 5Relative abundance of three major genera of ESKAPEE bacteria in water samples. Relative abundance was calculated based on operational taxonomic units (OTUs) assigned to the given genera indicating Pseudomonas spp. as the most abundant genus.
Figure 6PCR amplification with IntI1 primers. Positive amplification was observed for three isolates of E. coli, K.) pneumoniae, and P. aeruginosa. Lane 1, 1 kb DNA ladder (Thermo Fisher Scientific); lanes 2–5, PCR amplification with E. coli strains (HIC, H2D, M2B, R1B); lanes 6–8, PCR amplification with K. pneumoniae strains (H1E, H3C, P1D); lanes 8–10, PCR amplification with P. aeruginosa strains (H2A, H3B, R1A); lanes 11–12, PCR amplification with A. baumanii strains (H2K, M2D).